What is Leerink Partnrs’ Forecast for CNTA Q1 Earnings?

Centessa Pharmaceuticals plc (NASDAQ:CNTA) – Equities researchers at Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for Centessa Pharmaceuticals in a note issued to investors on Monday, March 24th. Leerink Partnrs analyst D. Risinger forecasts that the company will earn ($0.37) per share for the quarter. The consensus estimate for Centessa Pharmaceuticals’ current full-year earnings is ($1.60) per share. Leerink Partnrs also issued estimates for Centessa Pharmaceuticals’ Q2 2025 earnings at ($0.38) EPS and Q4 2025 earnings at ($0.41) EPS.

A number of other brokerages have also recently weighed in on CNTA. TD Cowen started coverage on shares of Centessa Pharmaceuticals in a research report on Tuesday, January 7th. They set a “buy” rating for the company. Morgan Stanley reaffirmed an “overweight” rating and set a $27.00 price objective on shares of Centessa Pharmaceuticals in a research report on Friday, March 7th. Finally, Guggenheim reissued a “buy” rating and issued a $28.00 target price on shares of Centessa Pharmaceuticals in a research report on Wednesday. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $26.00.

Centessa Pharmaceuticals Stock Down 0.2 %

Shares of CNTA opened at $14.51 on Wednesday. The company’s 50-day moving average price is $16.49 and its 200 day moving average price is $16.41. Centessa Pharmaceuticals has a 12-month low of $7.75 and a 12-month high of $19.09. The company has a current ratio of 21.52, a quick ratio of 21.52 and a debt-to-equity ratio of 0.15. The firm has a market cap of $1.91 billion, a P/E ratio of -9.48 and a beta of 1.54.

Centessa Pharmaceuticals (NASDAQ:CNTA) last announced its quarterly earnings results on Monday, March 24th. The company reported ($0.34) EPS for the quarter, beating the consensus estimate of ($0.38) by $0.04.

Hedge Funds Weigh In On Centessa Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in CNTA. Janus Henderson Group PLC lifted its stake in Centessa Pharmaceuticals by 279.2% in the fourth quarter. Janus Henderson Group PLC now owns 4,909,487 shares of the company’s stock worth $82,218,000 after acquiring an additional 3,614,623 shares during the last quarter. Foresite Capital Management VI LLC purchased a new stake in shares of Centessa Pharmaceuticals during the 4th quarter worth $20,994,000. Franklin Resources Inc. grew its stake in shares of Centessa Pharmaceuticals by 99.1% during the third quarter. Franklin Resources Inc. now owns 2,302,546 shares of the company’s stock worth $38,360,000 after purchasing an additional 1,145,823 shares in the last quarter. Point72 Asset Management L.P. increased its holdings in Centessa Pharmaceuticals by 54.1% in the third quarter. Point72 Asset Management L.P. now owns 2,715,663 shares of the company’s stock valued at $43,423,000 after buying an additional 953,659 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. increased its holdings in Centessa Pharmaceuticals by 22.0% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 5,119,027 shares of the company’s stock valued at $85,744,000 after buying an additional 924,027 shares during the last quarter. 82.01% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Centessa Pharmaceuticals

In other news, insider David M. Chao sold 7,000 shares of the company’s stock in a transaction on Monday, March 17th. The stock was sold at an average price of $17.17, for a total transaction of $120,190.00. Following the sale, the insider now owns 225,007 shares of the company’s stock, valued at approximately $3,863,370.19. This represents a 3.02 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Gregory M. Weinhoff sold 11,742 shares of Centessa Pharmaceuticals stock in a transaction on Monday, January 27th. The shares were sold at an average price of $16.47, for a total value of $193,390.74. Following the completion of the transaction, the insider now owns 159,782 shares of the company’s stock, valued at approximately $2,631,609.54. This trade represents a 6.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 260,168 shares of company stock valued at $4,309,568. 11.59% of the stock is currently owned by corporate insiders.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.